Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec™, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. Meningitec is a preservative free vaccine, which is registered in 23 countries throughout the world. N. meningitidis is a major cause of infectious disease worldwide, with a majority of cases occurring in children, and can lead to meningitis, sepsis and pneumonia. Without treatment, mortality is up to 90 percent, and death may occur within 48 hours. Nuron Biotech will work closely with Pfizer to ensure a seamless transition and to continue the ready availability of Meningitec to patients.

"Meningitec is a tremendous opportunity to expand Nuron Biotech's portfolio with a commercially successful vaccine with an established market," said Shankar Musunuri, Ph.D., MBA, Chief Executive Officer and Founder of Nuron Biotech. "The addition of Meningitec represents an important milestone toward bringing innovative biologics and vaccines to patients with unmet needs around the world. Vaccines such as Meningitec and HibTITER have established track records in the prevention of infectious disease, and we are excited to see such high quality life-saving products in our portfolio."

"We are planning to expand into markets with unvaccinated and under-vaccinated populations, helping us address public health needs around the world," said Richard C. Dinovitz, Vice President, Marketing and Business Development at Nuron Biotech. "Meningitec is a proven, life-saving, preventative vaccine. In the early 2000s, Meningitec played a pioneering role in reducing disease caused by N. meningitidis serogroup C by 93 percent in children in the U.K."

Source: Nuron Biotech Inc.